Skip to main content
. 2020 Jun 25;7(Suppl 1):30–35. doi: 10.1007/s40801-020-00196-6

Table 2.

Outcomes of patients who received oritavancin to expedite hospital discharge or oral step-down therapy at discharge

Oritavancin (n = 99) Oral step-down therapy (n = 100)
Hospital length of stay, mean (SD) days 3.5 (1.9) 5.6 (2.3)
SSTI-related 30-day readmissions, n (%) 7 (7.1%) 18 (18.0%)
SSTI 30-day readmissions with disease progression, n (%) 1 (1.0%) 7 (7.0%)

SSTI skin and soft tissue infection